The restenosis paradigm revisited: An alternative proposal for cellular mechanisms

Journal of the American College of Cardiology

Volumn 20, Issue 5, 1992, Pages 1284-1293

  Schwartz, Robert S ^a,b   Holmes Jr , David R ^a,b   Topol, Eric J ^a,b  

^a MAYO CLINIC   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTERY INTIMA PROLIFERATION; ARTICLE; CORONARY ARTERY OBSTRUCTION; HUMAN; HYPOTHESIS; PRIORITY JOURNAL; THROMBUS; VASCULAR SMOOTH MUSCLE; ANIMAL; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; DISEASE MODEL; EDITORIAL; INTIMA; PATHOLOGY; RECURRENT DISEASE;

ANIMAL; CORONARY DISEASE; CORONARY THROMBOSIS; DISEASE MODELS, ANIMAL; HUMAN; RECURRENCE; SUPPORT, NON-U.S. GOV'T; TUNICA INTIMA;

EID: 0026612517     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/0735-1097(92)90389-5     Document Type: Editorial

References (99)

1. Importance of stenosis morphology in the estimation of restenosis risk after elective percutaneous transluminal coronary angioplasty
2. Risk factors, time course and treatment effect for restenosis after successful percutaneous transluminal coronary angioplasty of chronic total occlusion
3. Influence of the methodology of percutaneous transluminal coronary angioplasty on restenosis
4. Relation to restenosis after percutaneous transluminal coronary angioplasty of vasomotion of the dilated coronary arterial segment
5. Restenosis after transluminal coronary angioplasty: a risk factor analysis
6. Coumadin and aspirin in prevention of recurrence after transluminal coronary angioplasty: a randomized study
7. Results of a randomized trial of heparin and aspirin vs. aspirin alone for prevention of acute closure IAC) and restenosis (R) after angioplasty (PICA) (abstr)
8. A randomized trial of aspirin in PTC A: Effect of high vs. low dose on major complications and restenosis [abstr]
9. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary anaplasty
10. Sulotroban during and after coronary angioplasty. A double-blind, placebo controlled study
11. Lack of effect of warfarin on the restenosis rate or on clinical outcome after balloon coronary angioplasty
12. Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty
13. A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty. M-HEART Group
14. Determinants of restenosis and lack of effect of dietary supplementation with eicosapentaenoic acid on the incidence of coronary artery restenosis after angioplasty
15. Reduction in the rate of early restenosis after coronary angioplasty by a diet supplemented with n-3 fatty acids
16. Randomised trial of fish oil for prevention of restenosis after coronary angioplasiy
17. Fish oil and restenosis rates (letter)
18. Fish oil supplements and restenosis after percutaneous transluminal coronary angioplasty
19. Usefulness of fish oil supplements in preventing clinical evidence of restenosis after percutaneous transluminal coronary angioplasty
20. Effect of eicosapeotaenoic acid on restenosis rate, clinical course and blood lipids in patients after percutaneous transluminal coronary angioplasty
21. Restenosis after coronary angioplasty is prevented by fish oil
22. Lipid lowering for the prevention of recurrent stenosis following coronary angioplasty (abstr)
23. Prevention of restenosis by lovastatin after successful coronary angioplasty
24. Failure of diltiazem to prevent restenosis after percutaneous transluminal coronary angioplasty
25. Effect of nifedipine on recurrent stenosis after percutaneous transluminal coronary angioplasty
26. Effect of short-term prostacyclin administration on restenosis after percutaneous transluminal coronary angioplasty
27. The new angiotensin converting onzyme inhibitor cilazapril does not prevent restenosis after coronary angioplasty the results of the MERCATOR trial (abstr)
28. Restenosis after coronary angioplasty Potential biologic determinants and the role of intimal hyperplasia
29. A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies
30. The role of platelets thrombin and hyperplasia in restenosis after coronary angioplasty
31. Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle proliferation
32. Hirudin, heparin, and placebo during deep arterial injury in the pig. The in vivo role of thrombin in platelet-mediated thrombosis
33. Restenosis after arterial angioplasty a hemorrhagic response to injury
34. Importance of antithrombin therapy during coronary angioplasty
35. Intimal proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplasty
36. Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty
37. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor
38. The pathological basis of angina pectoris
39. Angioscopic observation of the coronary luminal changes induced by percutaneous transluminal coranary angioplasty
40. Effectiveness of recombinant desulphatohirudin in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits
41. Thrombin and other potential mechanisms underlying restenosis
42. Role of platelets in smooth muscle cell proliferation and migration after vascular injury in the rat carotid artery
43. The biology of platelet-derived growth factor
44. Signal transduction by the platelet-derived growth factor receptor
45. Inhibition of neointimal smooth muscle accumulation afler angioplasty by an antibody to PDGF
46. Role of platelets in atherogenesis: relevance to coronary arterial restenosis after angioplasty
47. Regrowth of anterial endothelium. Denudation with minimal trauma leads to complete endothelial cell regrowth
48. Growth factor responses of human arterial endothelial cells in vitro
49. Insulin-like growth factor I stimulates elastin synthesis by bovine pulmonary arterial smooth muscle cells
50. The insulin-like growth factors: their putative rolein atheropenesis
51. Intrinsic bioactivity of insulin-like growth factor-binding proteins from vascular endothelial cells
52. Insulin-like growth factor I and protein kinase C activation stimulate pulmonary artery smooth muscle cell proliferation through separate but synergistic pathways
53. Effects of transforming growth factor-bela I on human arterial smooth muscle cells in vitro
54. Transforming growth factor-beta regulates the adhesive interactions between mononuclear cells and microvascular endothelium
55. Endothelial cell behavior after denudation injury is modulated by transforming growth factor-betal and fibronectin
56. Interlcukin 1 regulates heparin-binding growth factor 2 gene expression in vascular smooth muscle cells
57. Cytokine regulation of human monocyte interleukin-1 (IL-I) production in vitro. Enhancement of IL-1 production by interferon (IFN) gamma, tumour necresis factor-alpha. IL-2 and IL-1, and inhibition by IFN-alpha
58. Induction of intereukin-1 in human monocytes by the superantigen staphylococcal enteroloxin A requires the participation of T cells
59. IL-4 inhibits the expression of IL-8 from stimulated human monocytes
60. Secretion of interleukin-6 (IL-6) by human monocytes stimulated by muramyl dipeptide and tumour necrosis factor alpha
61. Differential regulation of interleukin-6, macrophage inflammatory protein-l, and JE/MCP-1 cytokine expression in macrophage cell lines
62. Heparin-binding growth factor-1 stimulation of human endothelial cells induces platelet-derived growth factor A-chain gene expression
63. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury
64. Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells
65. Angiotensin converting enzyme inhibition reduces re stenosis in experimental angioplasty (abstr)
66. Suppression of the vascular response to injury the role of angiotensin-converting enzyme inhibitors
67. Colchicine and anitineoplaslic therapy for the prevention of restenosis after perculaneous coronary interventions
68. Methotrexate and azathioprine fail to inhibit porcine coronary restenosis (abstr)
69. Cytotoxic effects of a recombinant chimeric toxin on rapidly proliferating vascular smooth muscle cells
70. Inhibition of 3H-thymidine incorporation by angiopeptin in the aorta of rabbits after balloon angioplasty
71. Peptide inhibition of accelerated transplant atherosclerosis
72. Inhibition of myointimal proliferation of the rat carotid artery by the peptides, angiopeptin and BIM 23034
73. Peptide inhibition of myointimal proliferation by angiopeptin a somatostatin analogue
74. Kinetics of cellular proliferation after arterial injury: I. Smooth muscle growth in absence of endothelium
75. Endothelial regeneration in the rat carotid artery and the significance of endothelial denudation in the pathogenesis of myointimal thickening
76. Endothelial regeneration. V. Inhibition of endothelial regrowth in arteries of rat and rabbit
77. Intimal injury and regrowth in the rabbit aorta: medial smooth muscle cells as a source of neointima
78. Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin
79. Effect of antiplatelet therapy on restenosis after experimental angioplasty
80. Vascular reactivity after balloon angioplasty in an atheroselerotic rabbit
81. Rabbit ear model of injury-induced arterial smooth muscle cell proliferation. Kinetics, reproducibility, and implications
82. Restenosis after balloon angioplasty: a practical proliferative model in porcine coronary arteries
83. Atherosclerotic lesions in coronary arteries of hyperlipidemic swine
84. Restenosis develops in four stages serial histologic studies in a coronary injury model (abstr)
85. Secretory products of macrophages
86. The porcine model for the understanding of thrombogenesis and atherogenesis
87. Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction
88. The fibroblast as a contractile cell: the myo-fibroblast
89. Myofibroblasts in human granulation tissue
90. Myofibroblast in human pathology
91. The myofibroblast. Possible derivation from macrophages in xanthogranuloma
92. Percutaneous coronary laser balloon angioplasty initial results of a multicenter experience
93. Early detection of restenosis after successful perculaneous transluminal coronary angioplasty by exercise-redistribution thallium scintigraphy
94. Usefulness of tomographic thallium-201 imaging for detection of restenosis after percutaneous transluminal coronary angioplasty
95. Silent ischemia after coronary angioplasty: evaluation of restenosis and extent of ischemia in asymptomatic patients by tomographic thallium-201 exercise imaging and comparison with symptomatic patients
96. Quantitative exercise thallibum-201 scintigraphy for predicting angina recurrence after percutaneous transluminal coronary angioplasty
97. Very early prediction of restenosis after successful coronary angioplasty anatomic and functional assessment
98. Stress lballium-201 imaging after coronary angioplasty predicts restenosis and recurrent symptoms
99. Very early prediction of restenosis after successful coronary angioplasty: how early is early and can we identify it?